Behavioural and Psychological Symptoms and Medications Presentation

Similar documents
Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit

THE BEHAVIOURAL VITAL SIGNS (BVS) TOOL

PSYCHOTROPIC SOLUTIONS

9/11/2012. Clare I. Hays, MD, CMD

12/17/2012. Unnecessary Drugs

Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care

Chapter 17. Psychoses. Classifications of Psychoses. Schizophrenia. Factors Attributed to Development of Psychoses

Vanderbilt & Qsource Webinar Series

Antipsychotic Medications

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

PATIENT INFORMATION LEAFLET ZOXADON TABLETS RANGE

Symbyax (Zyprexa [olanzapine] and Prozac [fluoxetine] combination)

Management of Behavioral Problems in Dementia

Management of Behavioral Symptoms in Dementia. Brenda Jordan, MS, ARNP, BC- PCM Dartmouth-Hitchcock Kendal

PSYCHOTROPIC SOLUTIONS

Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches

Elements for a Public Summary

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Recognition and Management of Behavioral Disturbances in Dementia

Behavior Problems: in Long Term Care and Assisted Living

Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD

Issues for Patient Discussion

Data Collection Worksheets

N.C. Nurse Aide I Curriculum MODULE T. Dementia and Alzheimer s Disease. DHSR/HCPR/CARE NAT I Curriculum - July

Integrating INTERACT into Interim Pharmacist Reviews

Antipsychotics in Dementia

Elements for a Public Summary. VI.2.1 Overview of disease epidemiology

DYSKINESIA SYMPTOM TRACKER

Schizophrenia. Class Objectives. Can someone be psychotic without having schizophrenia? 12/7/2011. Other psychotic disorders and causes

5/17/2017. Conflicts of Interest. Key Takeaways

Prior Authorization with Quantity Limit Program Summary

DOCTOR DISCUSSION GUIDE

Behavioral and Psychological Symptoms of dementia (BPSD)

Antipsychotics Detect, Select, Effect (P.I.E.C.E.S. 6 th Ed)

Preventing Falls in Older Adults A Matter of Safety

PERSISTENT PAIN PATHWAY - DATA RETRIEVAL WORKSHEET

Dementia Information Kit for HACC Workers

In 2020 mental and substance use disorders will surpass all physical diseases as a major cause of disability worldwide

The PD You Don t See: Cognitive and Non-motor Symptoms

DRAFT. Consultees are asked to consider and comment on the CEPP National Audit: Antipsychotics in Dementia document.

Dementia Care Principles

Package Leaflet: Information for the User. Kemadrin tablets 5 mg procyclidine hydrochloride

How Aging and Dementia Effect Resident Behaviors

Mental Health Issues in Nursing Homes. I m glad you asked.

Method. NeuRA Paliperidone August 2016

PSYCHOTROPIC MEDICATIONS IN LTC CHALLENGES AND OPPORTUNITIES FOR BEST PRACTICES

Behavioral Issues in Dementia. March 27, 2014 Dylan Wint, M.D.

Optimizing Clinical Communication in Parkinson s Disease:

Northumbria Healthcare NHS Foundation Trust. Your guide to understanding Delirium. Issued by Department of Medicine

III./3.1. Movement disorders with akinetic rigid symptoms

Delirium. Delirium is characterized by an acute onset (hours or days) and fluctuating course of deterioration in mental functioning.

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Non-Motor Symptoms of Parkinson s Disease

Alternatives to Physical Restraints

CEPP National Audit Antipsychotics in Dementia

Dementia Training Session for Carers. By Dr Rahul Tomar Consultant Psychiatrist

Session outline. Introduction to psychoses. Assessment of psychoses. Management of psychoses. Follow-up. Review.

Evaluation of Parkinson s Patients and Primary Care Providers

483.45(d) Unnecessary Drugs General. Each resident s drug regimen must be free from unnecessary drugs. An unnecessary drug is any drug when used

Nursing Process Focus: Patients Receiving Chlorpromazine (Thorazine)

Psychotropic Medication. Including Role of Gradual Dose Reductions

Extrapyramidal Symptoms Associated with Antipsychotic Use

U n i f i e d P a r k i n s o n s D i s e a s e R a t i n g S c a l e ( U P D R S )

Depression in the Eldery Handout Package

Every 67seconds, someone will develop Alzheimer's.

SECTION 1: as each other, or as me. THE BRAIN AND DEMENTIA. C. Boden *

Schizophrenia. This factsheet provides a basic description of schizophrenia, its symptoms and the treatments and support options available.

SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS

Active listening. drugs used to control anxiety and agitation. Antianxiety drugs

QM Reports Technical Specifications: Version 1.0

Assessment and management of behavioral and psychological symptoms of dementia

Seniors Health Strategic Clinical Network Restraint as a Last Resort

DBSA Survey Center Less Common Medication Side Effects Survey

Dementia & Delirium: Contents. Behaviours, Symptoms & Integrated Person-Centred Care. You & Your Care Dementia Pg.

Psychosis & Antipsychotic Medications

Lewy Body Disease. Dementia Education for the First Responder July 27, 2017

The psychological disorders

Delirium and Care Giving

Mellaril (thioridazine)

Residents Who Don t Sleep

Parkinsonian Disorders with Dementia

Community Pharmacy Dementia Audit

Presenter. Dr. Ronald Lucchino

BEHAVIORAL PROBLEMS IN DEMENTIA

OBJECTIVES. 1. Become familiar with common classes of psychotropic medications, indications for their use, and side effects.

NTG-EDSD v.1/ Instructions: For each question block, check the item that best applies to the individual or situation. Name of person: (3) First

BEHAVIOURAL ASSESSMENT FORM PLACEMENT SERVICES

Pharmacologyonline 1: (2009) ewsletter Rosanna Erra. Atypical Antipsychotic Drugs for the Treatment of BPSD. in Subjects with Dementia

Schizophrenia. Can someone be psychotic without having schizophrenia? 11/30/2008. Name that Psychotic Disorder! Other psychotic disorders and causes

PROJECTION: Worlds dementia population is expected to triple by 2050

Communication with Cognitively Impaired Clients For CNAs

May 2015 Clinical Nurse Educator Arohanui Hospice

Black holes taped on floor Redirection Music and activities Yellow straps across the door Remind other residents to use call bell when she comes in

DSW Conference th November 2008

National Task Group Early Detection Screen for Dementia (NTG-EDSD) Lucy Esralew, Ph.D. Chair, Screening NTG/AADMD

Understanding Parkinson s Disease Important information for you and your loved ones

Delirium. Quick reference guide. Issue date: July Diagnosis, prevention and management

Transcription:

1

2

Vover s research indicated that antipsychotic med are frequently used for individual presenting with disruptive behaviours. This often combined with physical restraints Efficacy of use not justify use. Effects are undesirable anticholinergic effects and extra-pyramidal effects 3

Research found the use of these drugs in residents with dementia increases the risk of mortality. These residents will have shorter life spans than their non drugged counterparts 4

5

Auditor General Report May 2005 6

7

8

Antipsychotic medications are used to treat a variety of symptoms in psychotic disorders, delusional depression and dementia. In order to identify a change, close monitoring i and documentation ti of behaviors is needed before and during use. Since these medications are not free of side effects, it is important to review the inventory of target behaviors prior to commencing the medication and on a regular basis after the drug treatment is initiated. Step 1: Initial Screen EVERY box on the BSMT must be completed with either a Y for yes or N for no. Absence of documentation ti (empty boxes) can not be interpreted t making review and evaluation of behaviour extremely difficult Section A must be completed for every client as part of a screening process. It is a tool to identify patients suitable to receive antipsychotics and documentation of that decision making process. **Note: For new admissions already on antipsychotic agents, start with Step 1 then skipping to Step 3. Current residents should have step 1 completed to establish a base line for behaviours. Rule Out Other Causes: Any of these clinical or environmental causes may be contributing to the behaviors and can likely be managed by other means than drug therapy. Check accordingly and review any identified possible causes to determine if applicable in this situation. Non-Drug Interventions. Due to risk of complications of medication, behavioural interventions should always be trialed completely and consistently prior to the consideration of any medicinal interventions. Document responses in comments section. 9

Medications have often been prescribed to manage behaviours for which it may have little or no effect. 10

Section B: Define and Describe Behaviour This section is to guide the health care professional in deciding if the behaviour may or may not be treatable with medication. A clear understanding of behaviour will facilitate this process. WILL NOT RESPOND To Antipsychotics. Medications have often been prescribed to manage behaviours for which it may have little or no effect. MAY Respond to Antipsychotics. In addition to indicating which behaviours are occurring, a narrative description is required to further ensure that the medication is being considered for the appropriate reason and could be feasibly managed by medication. 11

Wandering, Insomnia, Impaired memory, Lack of social behaviour skills, Poor self care practices, Fidgeting or nervous twitching, Inappropriate eliminations, Indifference to surroundings, Resists care, Hoarding, Restless pacing, Inappropriate Vocalizations Non pharmacological treatments fall into categories: safety focused care,-electronic wander monitoring, physical restraint i.e. broda chairs due to agitation/aggression resident education, - involves explanations to residents and families re symptoms and treatment behaviour focused care, supportive/comfort therapies, activity therapies, and environmental modification 12

Recent work by Kverno e tal state that in advanced dementia treatment goals shift from prolonging life to maximizing quality of life, dignity and comfort Delusions- theft, paranoia, false beliefs Hallucinations Hearing or seeing things, sensory, Picking Aggression grabbing/hitting, biting/spitting, swearing/screaming, temper outbursts, sexually aggressive Anxiety negative attitude, repetitive questions, tearful/guilt, restless/ unsettled, sleep patterns Agitation Elopement attempts, constant requests, interfering behaviour, pacing, shadowing Describe behaviour- Physically treatens staff when doesn t get her way. A narrative description of the behaviour is required to ensure that the medication is being considered for the appropriate reason and that the behaviour could be managed by that medication 13

It is strongly recommended that two weeks of behavior mapping be documented prior to initiating any drug therapy to serve as a baseline. The mapping will consist of completing Part A: Behaviour and Part B: Baseline Status. Mapping should be initiated by nursing upon identification of a behavioural concern in order to facilitate any required treatment regimes. After two weeks of behavior mapping, the situation will be reviewed by the physician to determine if the presenting behaviors are still within the treatment parameters and the plan for initiating drug therapy should go forth. A section has been designated for the physician and pharmacist to sign on a weekly basis. In a challenging unpredictable situation a physician may be visiting on a weekly basis although it is acknowledged that this is not a requirement. The physician may review the data at the end of the initial two weeks via fax or phone rather than on-site. **Note: Resident and staff safety should not be compromised in order to complete two weeks of behaviour mapping if initiation of medication sooner is clinically indicated. In this situation, at least one column of Step 2 should be completed retrospectively while proceeding with Step 3. Step 2 mapping is divided into two sections: Behaviours. Documentation of y for yes or n for no is required. This answer should best summarize the preceding 24hour time period. Severity and frequency documentation is not required here as that should be captured under either more detailed mapping or in the narrative progress record. Reportable Side Effects. The purpose is to provide an easy to follow guide to assess for the more common side effects of the drug therapy. Place a Y or N in the corresponding column to indicate if the side effect has been observed. 14

Decision making occurs after 2 weeks of behaviour mapping on page 2 15

Right Medications for the Right Reason The health care team will review the mapping and current status 16

Section C: Decision Making Should be completed by the Physician Medical Risks & Considerations. This section is designed to trigger a review of any medical condition(s) that may increase the risk of adverse events for the patient. The physician, upon reviewing the existing medical conditions will determine if the risks preclude the use of antipsychotics. Due to the potential for significant adverse effects, clear documentation of consent is required. Discussions surrounding usage should occur between the physician and resident/family. It is likely that this section may be completed at a later date than the initial screen once a more thorough assessment has been completed. The assessment data will likely include the initial behaviour mapping. 17

Step 3: Assessment Response to Medication The purpose of this step is to document an ongoing assessment of the patient following the commencement of drug therapy. Step 3 mapping should commence as soon as any drug therapy has begun and continue daily for a minimum of 2 weeks or longer as further medication adjustments are made, until the behavior is resolved or drug therapy is deemed ineffective. Again, Step 3 is divided into two sections. See Step 2 instructions with the exception of part B (Side Effects) where the assessor is asked to look at change in baseline to assist in determining if side effects are present. Upon completion of the trial, the attending physician, professional nurse and clinical pharmacist will review the behavior mapping and clinically assess the effectiveness of the drug therapy to determine if this drug therapy will be continued. **Note: An observed change in any of these side effects should be reported to physician. 18

- Extrapyramidal (Parkinsonian) effects which include tremor (pill rolling), stiffness in limbs (cog- wheel rigidity), idit shuffling gait, drooling, stooped or leaning posture, acute dystonias (often of the neck). These symptoms may be a warning of the possible development of tardive dyskinesia, especially if they occur early in the course of treatment. Tremors, drooling, cogwheeling "Tardive Dyskinesia is a frequent, often irreversible, side effect of antipsychotic agents. Tardive dyskinesia presents as a combination of one or more of the following: - involuntary movements of the face, jaws, mouth, lips and eyes; -movements may be accompanied by uncontrolled grunting, groaning and/or lip smacking - involuntary movements of the limbs (which may lead to gait disturbance) Tardive dyskinesia is usually a complication of long term antipsychotic use (months to years of therapy) but may occasionally develop after only a few months of continuous use. Other side effects include: - Akathisia - increased restlessness which usually worsens with increasing doses of medication -Increased ddrowsiness/sedation d -Dehydration contributing to constipation and dry mouth -Weight gain in the presence of diabetes -Excessive or unnecessary disability 19

20

Step 4: Maintenance Record Documentation of the ongoing monitoring is tracked here. This will provide the physician with information to complete the required monthly assessment. This section is a continuation of Step 3 and the items being assessed are exactly the same. One new item to be measured it the number of PRNs used in the time period being assessed. This shall be entered as a numeric value. Note: The scoring has changed. (It is no longer Y or N ) It will be scored as behavior that best reflects the frequency of behaviors and side effects occurring over the 30 days prior to the day being scored 0 behavior/side effect did not occur. 1 behavior/side effect occurred once 2 behavior/side effects present more than once but less than every day 3 behavior/side effects present daily 4 behavior/side id effects present more than once daily Enter a numeric value from 0 through 4 in EVERY box. *Documentation of the presence of a particular behavior or side effect on the BSMT does not replace regular documentation in the progress record. Complete documentation of assessments is still required. One column should be dated and completed each month. The BSMT and all other mapping tools used will become part of the patient s resident s permanent record. 21

22

23

24

Given the side effects of these drugs, it is important to keep length of exposure to antipsychotic medications to a minimum when they are used for BPSD. Once success has been achieved, consideration of a gradual decrease in medication dose, again in the presence of behaviour mapping, is indicated. Initiate medication reductions after the behaviours have been successfully resolved for six months. 25

26

27

28

29

30